Clinical Trial Detail

NCT ID NCT02003209
Title Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)

Her2-receptor positive breast cancer


Carboplatin + Docetaxel + Goserelin + Pertuzumab + Trastuzumab

Carboplatin + Docetaxel + Pertuzumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST